Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target Lowered to $11.00 at HC Wainwright

Reviva Pharmaceuticals (NASDAQ:RVPH) had its target price reduced by HC Wainwright from $14.00 to $11.00 in a research note published on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

RVPH has been the subject of a number of other research reports. Roth Mkm assumed coverage on Reviva Pharmaceuticals in a research note on Friday, January 10th. They issued a “buy” rating and a $7.00 price target for the company. D. Boral Capital reissued a “buy” rating and issued a $15.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday. Maxim Group raised shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Friday, January 10th. Finally, Roth Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 10th. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $11.40.

Reviva Pharmaceuticals Price Performance

Shares of NASDAQ:RVPH opened at $1.94 on Wednesday. The firm’s 50 day simple moving average is $1.68 and its two-hundred day simple moving average is $1.33. The company has a market capitalization of $64.88 million, a P/E ratio of -1.75 and a beta of -0.12. Reviva Pharmaceuticals has a 1-year low of $0.60 and a 1-year high of $4.83.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Reviva Pharmaceuticals stock. Drive Wealth Management LLC acquired a new position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 20,000 shares of the company’s stock, valued at approximately $36,000. Drive Wealth Management LLC owned approximately 0.06% of Reviva Pharmaceuticals as of its most recent SEC filing. 63.18% of the stock is currently owned by institutional investors and hedge funds.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.